Test Drive Our New Site! We have some improvements in the works that we're excited for you to experience. Click here to try our new, faster, mobile friendly beta site. We will be maintaining our current version of the site thru the end of 2024, so you can switch back as our improvements continue.
Legislation Quick Search
04/23/2024 11:03 AM
Pennsylvania House of Representatives
https://www.legis.state.pa.us/cfdocs/Legis/CSM/showMemoPublic.cfm?chamber=H&SPick=20210&cosponId=37350
Share:
Home / House Co-Sponsorship Memoranda

House Co-Sponsorship Memoranda

Subscribe to PaLegis Notifications
NEW!

Subscribe to receive notifications of new Co-Sponsorship Memos circulated

By Member | By Date | Keyword Search


House of Representatives
Session of 2021 - 2022 Regular Session

MEMORANDUM

Posted: May 19, 2022 11:34 AM
From: Representative Christopher B. Quinn
To: All House members
Subject: Scheduling substances found in Kratom as Schedule I controlled substances
 
Soon, I will be introducing legislation to place two substances found in Kratom, Mitragynine and 7-Hydroxymitragynine, on the list of Schedule I controlled substances under the Commonwealth’s Controlled Substance, Drug, Device & Cosmetic Act. Mitragynine is an indole-based alkaloid that is found in the leaves of the Kratom tree. 7-Hydroxymitragynine is the active metabolite of Mitragynine.
For background, Kratom is derived from a tropical tree (Mitragyna speciosa) from Southeast Asia. The leaves of this tree contain compounds that could cause hallucinatory effects. Currently, Kratom is a legal substance that is readily available and commonly sold as a pill, capsule, or extract. Kratom can be addictive since the effects are like that of opioids and stimulants.
At the present time, Kratom is not a controlled substance under Federal or State law. However, the Food and Drug Administration (FDA) has yet to approve Kratom for medical use. Of note, the Drug Enforcement Administration (DEA) has listed Kratom as a “Drug and Chemical of Concern.”
Kratom is believed to act on opioid receptors. At low doses, Kratom acts as a stimulant, making users feel more energetic. At higher doses, it reduces pain and may bring on euphoria. At very high doses, it acts as a sedative, making users quiet and sleepy.
According to the Mayo Clinic, poison control centers in the United States received about 1,800 reports involving the use of Kratom from 2011 through 2017, including reports of death. About half of these exposures resulted in serious negative outcomes such as seizures and high blood pressure. Five of the seven infants who were reported to have been exposed to Kratom went through withdrawal.
As a Commonwealth, we do not need to wait for the Federal government to control a substance before acting. As Kratom is currently unregulated, products containing Kratom can be purchased over the counter without age restriction.
I believe it is important to protect the health and safety of the citizens of this Commonwealth by placing these two substances on the Commonwealth’s list of Schedule I controlled substances.
Please join me in co-sponsoring this important piece of legislation.
 



Introduced as HB2711